NIAID Preclinical Development Support: Essential Core Activities
- Institution
- ADVANCED BIOSCIENCE LABORATORIES, INC., MD
- Principal investigator
- Timothy R Fouts
- Funding
- $333K
- Duration
- 2017–2024
Moonbase score
Still being scored
Abstract
NIAID Preclinical Development Support: The purpose of this contract is to provide all aspects of the development, manufacture, IND enabling preclinical testing, and the production of regulatory documents for prototype HIV-1 prophylactic vaccines for human clinical trials. This includes all types of HIV-1 vaccines including DNA plasmids, viral vectors, and protein antigens. These capabilities will allow NIAID to more rapidly and efficiently close development and production gaps for HIV vaccines. Activities would be for he small-scale production, preclinical testing and documentation leading to Investigational New Drug (IND) submission for Phase I, II, and III clinical testing. Activities include assisting in the identification, testing, and development of products; participation in and managing preclinical testing including in vitro laboratory testing, immunogenicity testing, efficacy studies, and toxicology testing using laboratory animals; and utilize GMP production protocols to produce promising products. Furthermore, the Contractor shall also maintain inventories of products, provide quality assurance and quality control, provide the appropriate regulatory documentation, and develop and manage a database that tracks the preclinical development of the products.
LOADING MOONBASE SCORE
Questions for ADVANCED BIOSCIENCE LABORATORIES, INC.
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Advanced Bioscience Laboratories, Inc.Not yet scored
Resource to Advance Pediatrics and HIV Prevention Science (RAPPS): Quality Assurance/Quality Control (QA/QC) Support
Peter Silvera · $551K · 2025–2026
- NIH · Advanced Bioscience Laboratories, Inc.Not yet scored
Next Generation Development of Broadly Neutralizing HIV Antibodies for Prevention
Timothy Fouts · $181K · 2025–2028
- NIH · Advanced Bioscience Laboratories, Inc.Not yet scored
NIAID Preclinical Development Support - Production of a HIV gp145 Clade C Trimer Protein
Timothy Fouts · $25K · 2025